Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma

Published:2015-03-01 Issue:5 Volume:72 Page:353-360
ISSN:1079-2082
Container-title:American Journal of Health-System Pharmacy
language:en
Short-container-title:

Author:

McBride Ali¹,Klaus Jeff O.²,Stockerl-Goldstein Keith³

Affiliation:

1. Department of Pharmacy, University of Arizona Cancer Center, Tucson

2. Hematologic Malignancies/Stem Cell Transplant, Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, MO

3. Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis

Publisher

Oxford University Press (OUP)

Subject

Health Policy,Pharmacology

Link

http://academic.oup.com/ajhp/article-pdf/72/5/353/28320493/ajhp0353.pdf

Reference50 articles.

1. Cancer statistics, 2011;Siegel;CA Cancer J Clin,2011

2. Multiple myeloma;Anderson;J Natl Compr Canc Netw,2011

3. Multiple myeloma and occupation. A systematic review of the literature;Perrotta;Ir J Med Sci,2006

4. Multiple myeloma and farming. A systematic review of 30 years of research. Where next?;Perrotta;J Occup Med Toxicol,2008

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advancements in nanomaterial-mediated ferroptosis-induced cancer therapy: Importance of molecular dynamics and novel strategies;Life Sciences;2024-06

2. Flavonoid Diversity and Roles in the Lipopolysaccharide-Mediated Inflammatory Response of Monocytes and Macrophages;Future Medicinal Chemistry;2024-01

3. The role of E3 ubiquitin ligases in bone homeostasis and related diseases;Acta Pharmaceutica Sinica B;2023-10

4. Heart Failure Among Patients with Multiple Myeloma Treated with Carfilzomib-Based Versus Non–Carfilzomib-Based Regimens in the United States by Race;Clinical Lymphoma Myeloma and Leukemia;2023-08

5. CD69 marks a subpopulation of acute myeloid leukemia with enhanced colony forming capacity and a unique signaling activation state;Leukemia & Lymphoma;2023-05-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3